Oncocyte Corporation
OCX
Get informed when a big investor buys or sells
+ FollowMarket Cap$108.82M
Close$
$-1.65
151.7% downside
Current Fair Value
151.7% downsideOvervalued by 151.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $108.82 Million |
|---|---|
| Enterprise Value | $93.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.65 |
| Beta | 0.99 |
| Outstanding Shares | 36,750,000 |
Return
| Return on Equity | 231.74% |
|---|---|
| Return on Assets | -167.64% |
| Return on Invested Capital | -261.39% |
Valuation & Multiples
| P/E Ratio | -2.22 |
|---|---|
| PEG | -14.23 |
| Price to Sales | - |
| Price to Book Ratio | -3.2 |
| Enterprise Value to Revenue | 56.1 |
| Enterprise Value to EBIT | -1.87 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 10, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About OncoCyte Corp
57 employees
CEO: Joshua Riggs OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the Uni...